secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-08-21T23:59:59+00:00
Accession:  0001558370-24-012413
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path reports solid tumor patient response to BP1001-A; AML patients show extended remission
--------------------------------------------------------------------------------

- First patient at 90 mg/m2 dose of BP1001-A had 15% tumor reduction and stable disease after 6 cycles.
- Patient is elderly female with gynecologic cancer, heavily pretreated with chemotherapy and surgeries.
- Two elderly AML patients in Phase 2 triple combo (prexigebersen/decitabine/venetoclax) remain in complete remission: one at 16 cycles/21 months, another at 12 cycles/14 months.
- Phase 1b of BP1001-A expected to begin after three monotherapy dose cohorts; will test combo with paclitaxel and gemcitabine.
- Management highlights platform potential for targeted protein inhibition with favorable safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024012413/0001558370-24-012413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024012413/bpth-20240821x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-012413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer